No­var­tis en­lists Mol­e­c­u­lar Part­ners on ra­di­oli­gand ther­a­py dis­cov­ery; Galera blames CRO er­ror for PhI­II fail­ure — claims suc­cess af­ter all

A set­back in Covid-19 didn’t stop No­var­tis from team­ing up with Mol­e­c­u­lar Part­ners again. And this time, they will be look­ing for ra­dio­phar­ma­ceu­ti­cals.

Hav­ing bet big on the field, No­var­tis now wants to test a dif­fer­ent way of build­ing these ther­a­pies — by con­ju­gat­ing ra­di­oli­gands with Mol­e­c­u­lar Part­ners’ an­ti­body mimet­ics.

DARPin, as the class of pro­teins is known, are ge­net­i­cal­ly en­gi­neered pro­teins that can tar­get spe­cif­ic anti­gens just like tra­di­tion­al an­ti­bod­ies but are much small­er. When ap­plied to ra­di­oli­gand ther­a­pies, it promis­es to de­liv­er can­cer-killing ra­di­a­tion pre­cise­ly to tu­mor cells (while spar­ing healthy ones).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.